Clinical Focus
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Giredestrant Plus Everolimus in ESR1-Mutated Breast Cancer
2
FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC
3
FDA Approves Pertuzumab Biosimilar in HER2-Positive Breast Cancer
4
Cretostimogene Cuts Recurrence Risk by 68% in Intermediate-Risk NMIBC
5
